• Marinomed set Tacrolimus eyedrops as first product for planned entry into compounding market, targeting faster monetization of Marinosolv platform through partner-led commercialization.
• First partner revenues expected in Q4 2026 or early 2027, with management targeting rapid growth in 2027.
• Strategy aims to serve niche, high-need ocular inflammation patients via compounded product route, supporting longer-term development of Tacrosolv as a licensed pharmaceutical product.
• Program centers on Marinosolv-based aqueous formulation positioned to improve tolerability versus current off-label or oil-based alternatives, with stated efficacy at 10x lower concentration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marinomed Biotech AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2325054_en), on May 11, 2026, and is solely responsible for the information contained therein.